GO:0062172 lutein catabolic process: Carotenoid Breakdown Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0062172 (lutein catabolic process) is the biological process describing the chemical reactions and pathways that break down lutein, a xanthophyll carotenoid.
• Lutein is a non-provitamin A carotenoid that cannot be converted to vitamin A, so its catabolism governs its clearance and the fate of its oxidation products.
• Lutein bioavailability and tissue levels are modulated by genetic factors, which indirectly influence how much substrate enters catabolic routes.
• Lutein and its derivatives interact with membrane physicochemical environments, which affects their stability and breakdown.
• Lutein catabolic process is relevant to eye diseases, inflammation, cardiotoxicity and acute lung injury models where lutein exerts protective effects [1,3,5,7].
• CRISPR knockout, point-mutation, knock-in and overexpression models are key tools to dissect the enzymes and regulators of lutein catabolism.
Description
GO:0062172, lutein catabolic process, is the biological process comprising the chemical reactions and pathways that result in the breakdown of lutein, a xanthophyll carotenoid widely studied for its roles in eye health and antioxidant defense [1,2]. Lutein is a non-provitamin A carotenoid, meaning it is not converted to retinol, so its physiological fate depends on absorption, distribution and eventual catabolism. Understanding this catabolic process is important because the balance between lutein accumulation and degradation influences its protective effects in tissues such as the retina, intestinal epithelium, heart and lung [1,3,5,7]. Lutein bioavailability is itself modulated by genetic factors, which can determine how much lutein is available as substrate for catabolic enzymes. In addition, the biologic activity of carotenoids such as lutein is related to distinct membrane physicochemical interactions, which can affect their susceptibility to oxidation and breakdown. Because lutein is a carotenoid of biotechnological importance, knowledge of its catabolic process also supports metabolic engineering and synthetic biology efforts. This article summarizes the definition, mechanism, key genes, disease links and research methods for GO:0062172, with all factual statements supported by published literature.
lutein catabolic process At A Glance
| GO ID | GO:0062172 |
|---|---|
| GO term | lutein catabolic process |
| Ontology | biological_process |
| Synonym | lutein breakdown; lutein catabolism; lutein degradation |
| Definition | The chemical reactions and pathways resulting in the breakdown of lutein. |
| Major function | Breakdown and clearance of the xanthophyll carotenoid lutein and its oxidation products. |
| Related molecule | Lutein, a non-provitamin A carotenoid |
| Related process | Carotenoid metabolism and membrane-associated antioxidant chemistry [2,6] |
| Disease relevance | Eye diseases, inflammation, cardiotoxicity and acute lung injury [1,3,5,7] |
What Is GO:0062172?
According to the Gene Ontology, GO:0062172 (lutein catabolic process) is defined as the chemical reactions and pathways resulting in the breakdown of lutein. In other words, it covers all enzymatic and non-enzymatic steps that convert lutein into degradation products, including oxidation, cleavage and further conversion of intermediates. The term is a biological_process and is also known by the synonyms lutein breakdown, lutein catabolism and lutein degradation. Because lutein is a non-provitamin A carotenoid, its catabolic process is distinct from pathways that generate retinoids from provitamin A carotenoids. The process is influenced by the physicochemical environment of membranes, which can alter carotenoid stability and reactivity, and by genetic factors that modulate lutein bioavailability and thus substrate availability.
Why Is lutein catabolic process Important in Cell Biology?
Lutein catabolic process matters because the steady-state level of lutein in tissues depends not only on intake and bioavailability but also on how quickly it is broken down [1,8]. Lutein is a non-provitamin A carotenoid with protective effects in several experimental disease models, including cisplatin-induced intestinal inflammation and cardiotoxicity, rheumatoid arthritis and acute lung injury, so its catabolism can directly influence the duration and magnitude of these effects [3,4,5,7]. Genetic factors that modulate lutein bioavailability can shift the amount of substrate entering catabolic pathways, linking inter-individual variation to differences in tissue protection. Membrane physicochemical interactions of carotenoids such as lutein also affect their stability and breakdown, which is relevant to designing stable formulations and functional foods. Finally, lutein is a carotenoid of biotechnological importance, and understanding its catabolic process supports metabolic engineering of carotenoid-producing organisms.
• Determines the tissue half-life and clearance of lutein, a non-provitamin A carotenoid.
• Influences the protective effects of lutein in eye diseases.
• Modulates lutein action in cisplatin-induced intestinal inflammation.
• Affects lutein suppression of MAPK/NF-kB signaling in rheumatoid arthritis models.
• Impacts lutein protection against cisplatin-induced cardiotoxicity.
• Contributes to lutein effects in acute lung injury via PPAR-gamma/PI3K/AKT/NLRP3 signaling.
• Interacts with membrane physicochemical properties that govern carotenoid stability.
• Is influenced by genetic factors controlling lutein bioavailability.
• Supports biotechnological production and engineering of carotenoids.
• Provides a target for CRISPR-based dissection of carotenoid metabolic enzymes.
What Happens During lutein catabolic process?
Substrate availability and uptake of lutein
In simple terms: Before lutein can be broken down, it must first be absorbed and delivered to tissues.
Lutein catabolic process begins with the availability of lutein as a substrate, which depends on dietary intake, absorption and transport. Genetic factors are known to modulate lutein bioavailability, meaning that polymorphisms in absorption or transport pathways can change how much lutein reaches tissues and thus how much substrate is available for catabolism. Lutein is a non-provitamin A carotenoid, so it is not converted to vitamin A and instead must be cleared or degraded through catabolic routes. The biologic activity of carotenoids such as lutein is related to distinct membrane physicochemical interactions, which can affect how lutein partitions into membranes and how accessible it is to degrading reactions.
Oxidative and cleavage reactions
In simple terms: Once in tissues, lutein can be chemically modified and cleaved into smaller products.
The core of lutein catabolic process involves chemical reactions that break down the lutein molecule, including oxidative modifications and cleavage of the carotenoid backbone. Because lutein is a carotenoid of biotechnological importance, its degradation chemistry is studied in both biological and industrial contexts. Membrane physicochemical interactions influence the reactivity of carotenoids, and these interactions can shape the rate and products of lutein breakdown. The resulting oxidation products and cleavage fragments are part of the catabolic pathway and can themselves have biological activity, although the exact enzymes and intermediates remain an active area of research.
Regulation by cellular signaling and stress
In simple terms: Cellular stress and signaling pathways can change how fast lutein is used or broken down.
Lutein catabolic process does not occur in isolation; it is influenced by cellular signaling and stress states. In models of cisplatin-induced intestinal inflammation, lutein reduces inflammation by inhibiting ROS-mediated MAPK/NF-kB pathways, indicating that redox and inflammatory signaling intersect with lutein metabolism. Similarly, lutein attenuates rheumatoid arthritis progression by suppressing MAPK/NF-kB signaling and MMP3 and MMP13 expression in fibroblast-like synoviocytes. In acute lung injury induced by limb ischemia-reperfusion, lutein acts through PPAR-gamma/PI3K/AKT/NLRP3 signaling. These pathways can alter the oxidative environment and thus the rate of lutein catabolism.
Tissue-specific outcomes of lutein breakdown
In simple terms: Different tissues handle lutein breakdown differently, which affects disease outcomes.
The consequences of lutein catabolic process are tissue-specific. In the eye, lutein supplementation is studied for eye diseases, and its breakdown affects the duration of its protective presence in retinal tissues. In the heart, lutein reduces cisplatin-induced cardiotoxicity, and its catabolism may influence the persistence of this protection. In the lung, lutein alleviates acute lung injury through PPAR-gamma/PI3K/AKT/NLRP3 signaling, linking catabolic turnover to inflammatory resolution. These examples show that lutein catabolic process is not merely a clearance mechanism but a determinant of tissue protection.
Key Genes Involved in GO:0062172 lutein catabolic process
The following genes and proteins have been implicated in lutein biology, carotenoid metabolism, bioavailability and the signaling pathways that intersect with lutein catabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BCO1 | Beta-carotene oxygenase 1, a carotenoid cleavage enzyme | Model for carotenoid cleavage enzyme family; lutein is non-provitamin A so BCO1 is a comparative reference |
| BCO2 | Beta-carotene oxygenase 2, a carotenoid cleavage enzyme | Candidate enzyme for xanthophyll cleavage and lutein catabolism |
| CD36 | Fatty acid translocase involved in carotenoid uptake | Modulates lutein bioavailability and substrate availability |
| SCARB1 | Scavenger receptor class B member 1, carotenoid transport | Genetic factor influencing lutein bioavailability |
| ABCA1 | ATP binding cassette subfamily A member 1, lipid transport | Potential modifier of lutein distribution and catabolism |
| APOA1 | Apolipoprotein A1, lipoprotein component | Affects carotenoid transport and tissue delivery |
| APOB | Apolipoprotein B, lipoprotein component | Affects carotenoid transport and tissue delivery |
| CYP enzymes | Cytochrome P450 oxidative enzymes | Candidate oxidative enzymes in carotenoid breakdown |
| MAPK1 | Mitogen-activated protein kinase 1 | Lutein inhibits ROS-mediated MAPK signaling in inflammation models |
| MAPK14 | p38 MAPK, stress-activated kinase | Lutein modulates MAPK/NF-kB pathways [3,4] |
| NFKB1 | Nuclear factor kappa B subunit 1 | Lutein suppresses NF-kB signaling in inflammation [3,4] |
| MMP3 | Matrix metallopeptidase 3 | Lutein suppresses MMP3 in rheumatoid arthritis synoviocytes |
| MMP13 | Matrix metallopeptidase 13 | Lutein suppresses MMP13 in rheumatoid arthritis synoviocytes |
| PPARG | Peroxisome proliferator activated receptor gamma | Lutein acts through PPAR-gamma signaling in acute lung injury |
| PIK3CA | PI3K catalytic subunit alpha | Lutein modulates PI3K/AKT signaling in acute lung injury |
| AKT1 | AKT serine/threonine kinase 1 | Lutein modulates PI3K/AKT signaling in acute lung injury |
| NLRP3 | NLR family pyrin domain containing 3 | Lutein modulates NLRP3 inflammasome in acute lung injury |
| TJP1 | Tight junction protein 1, epithelial barrier | Lutein protects intestinal barrier in cisplatin-induced inflammation |
How Is lutein catabolic process Regulated?
Lutein catabolic process is regulated at multiple levels. Substrate availability is controlled by genetic factors that modulate lutein bioavailability, including genes involved in absorption and transport. The oxidative environment of the cell influences the rate of lutein breakdown, and lutein itself modulates ROS-mediated MAPK/NF-kB signaling, creating feedback between catabolism and inflammatory signaling [3,4]. In acute lung injury, lutein acts through PPAR-gamma/PI3K/AKT/NLRP3 signaling, indicating that these pathways can regulate the cellular context in which lutein is metabolized. Membrane physicochemical interactions also regulate carotenoid stability and thus the likelihood of catabolic processing. Finally, biotechnological studies of carotenoid metabolism provide insight into the enzymatic regulation of lutein breakdown.
lutein catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BCO2 | Carotenoid cleavage and lutein catabolism | Knockout cell model with lutein treatment |
| CD36 | Lutein bioavailability and uptake | Overexpression and knockout models in intestinal cells |
| NFKB1 | Inflammation and lutein protection | Point-mutation and knockout models in inflammation [3,4] |
| PPARG | Acute lung injury and lutein signaling | Knockout and knock-in models in lung epithelial cells |
| NLRP3 | Inflammasome and acute lung injury | Knockout models with lutein treatment |
Lutein catabolic process and eye diseases
Lutein supplementation is studied for eye diseases, and the catabolic process that clears lutein can influence how long protective concentrations persist in ocular tissues. Because lutein is a non-provitamin A carotenoid, its ocular benefits depend on local accumulation and turnover rather than conversion to retinoids. Genetic factors that modulate lutein bioavailability can also affect how much lutein reaches the eye and how much is available for catabolism. Understanding lutein catabolic process may therefore help optimize supplementation strategies for eye health.
Lutein catabolic process and inflammation
Lutein reduces cisplatin-induced intestinal inflammation by inhibiting ROS-mediated MAPK/NF-kB pathways, and its catabolism can affect the duration of this anti-inflammatory action. In rheumatoid arthritis, lutein attenuates disease progression by suppressing MAPK/NF-kB signaling and MMP3 and MMP13 expression in fibroblast-like synoviocytes. These findings link lutein catabolic process to the resolution of inflammatory signaling. In acute lung injury, lutein alleviates injury through PPAR-gamma/PI3K/AKT/NLRP3 signaling, further connecting lutein metabolism to inflammation control.
Lutein catabolic process and cardiotoxicity
Lutein, a non-provitamin A carotenoid, reduces cisplatin-induced cardiotoxicity, indicating a protective role in the heart. The catabolic process that breaks down lutein may determine how long this cardioprotection lasts and what degradation products are formed. Because carotenoid biologic activity is related to membrane physicochemical interactions, the cardiac membrane environment may influence lutein stability and breakdown. These observations support further study of lutein catabolic process in cardiovascular toxicology.
Lutein catabolic process and biotechnology
Lutein is a carotenoid of biotechnological importance, and its catabolic process is relevant to metabolic engineering of carotenoid-producing organisms. Understanding the enzymes and reactions that degrade lutein can help improve yields in biotechnological production systems. Genetic factors that modulate lutein bioavailability in humans also inform how catabolism affects nutritional outcomes. Thus, lutein catabolic process bridges human health and industrial biotechnology.
From lutein catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Which enzymes cleave lutein? | CRISPR knockout of candidate carotenoid cleavage enzymes |
| How does lutein bioavailability affect catabolism? | Knockout and overexpression of transport genes such as CD36 |
| Does a point mutation alter lutein catabolic rate? | CRISPR point-mutation knock-in cell lines |
| How does lutein catabolism affect inflammation? | Knockout of NFKB1 or MAPK genes with lutein treatment [3,4] |
| What is the role of PPAR-gamma in lutein action? | Knock-in and knockout models in lung cells |
| Can lutein breakdown be tracked in live cells? | Tagged knock-in of catabolic enzymes with fluorescent tags |
How to Study the lutein catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Identify enzymes required for lutein catabolism |
| CRISPR point mutation | Effect of specific amino acid changes | Test catalytic residues in carotenoid cleavage enzymes |
| CRISPR knock-in | Tagged or mutant protein expression | Track enzyme localization and dynamics |
| HPLC-MS | Lutein and metabolite levels | Quantify lutein catabolic rate |
| RNA-seq | Transcriptome changes | Find genes co-regulated with lutein catabolism |
| Proteomics | Protein abundance and modifications | Identify catabolic enzymes and regulators |
| ROS and NF-kB assays | Oxidative stress and inflammatory signaling | Link lutein catabolism to inflammation [3,4] |
| PPAR-gamma/PI3K/AKT/NLRP3 assays | Signaling pathway activity | Study lutein action in acute lung injury |
CRISPR screening and gene editing
CRISPR knockout and knock-in screens can identify genes required for lutein catabolic process. By disrupting candidate carotenoid cleavage enzymes and transport proteins, researchers can measure changes in lutein levels and degradation products. Point mutations can be introduced to test catalytic residues, while tagged knock-ins allow tracking of enzyme localization. These approaches are supported by knowledge of genetic factors that modulate lutein bioavailability.
Analytical detection of lutein and its products
High-performance liquid chromatography and mass spectrometry are used to quantify lutein and its catabolic products in cells and tissues. These methods are essential for measuring the rate of lutein catabolic process and for identifying intermediates. Because carotenoid biologic activity depends on membrane physicochemical interactions, sample preparation must preserve native membrane environments. Such analyses support studies in eye, heart, lung and intestinal models [1,3,5,7].
Cell-based assays for inflammation and oxidative stress
Lutein catabolic process can be studied in cell models of inflammation and oxidative stress. Assays measuring ROS, MAPK/NF-kB signaling and MMP expression reveal how lutein breakdown affects cellular responses [3,4]. In acute lung injury models, PPAR-gamma/PI3K/AKT/NLRP3 signaling can be monitored to link catabolism to injury resolution. These assays are compatible with CRISPR-edited cell lines.
Bioinformatics and pathway analysis
Bioinformatics tools can integrate transcriptomic, proteomic and metabolomic data to predict enzymes and regulators of lutein catabolic process. Pathway enrichment using GO:0062172 helps identify co-expressed genes and candidate regulators. Genetic association data on lutein bioavailability can be combined with expression data to prioritize genes. These analyses guide the design of CRISPR experiments and functional validation.
How CRISPR Can Be Used to Study GO:0062172 lutein catabolic process
Knockout
CRISPR knockout of candidate genes such as BCO2, CD36 or NFKB1 can reveal their roles in lutein catabolic process. Loss-of-function models allow measurement of lutein accumulation or persistence and its downstream effects on inflammation and oxidative stress [2,3,4]. Knockout of transport genes can also test how bioavailability genes influence catabolism.
Point Mutation
Point mutations introduced by CRISPR can test the catalytic activity of enzymes hypothesized to break down lutein. By mutating predicted active-site residues, researchers can distinguish enzymes that directly catabolize lutein from those with indirect roles. Point mutations in signaling genes such as NFKB1 can also clarify how lutein catabolism intersects with inflammation [3,4].
Knock-in
Knock-in of fluorescent or epitope tags into catabolic enzymes enables real-time tracking of lutein breakdown in cells. Tagged knock-in models can reveal where lutein catabolic process occurs within organelles and how it responds to stimuli. Knock-in of disease-associated variants in bioavailability genes can model inter-individual differences in lutein metabolism.
Overexpression
Overexpression of candidate enzymes or transport proteins can increase lutein catabolic flux and reveal rate-limiting steps. Overexpression models complement knockout studies by testing sufficiency rather than necessity. Overexpression of PPARG or PI3K/AKT components can also test how signaling drives lutein-related protection in lung injury.
How EDITGENE Supports lutein catabolic process Research
Researchers studying lutein catabolic process-related genes often need to determine whether a candidate gene is causally involved in lutein breakdown, how specific mutations affect enzyme activity, and whether altered catabolism changes disease-relevant outcomes. EDITGENE provides CRISPR-based cell model services that enable these causal experiments in a controlled and reproducible manner.
Contact EDITGENE today to design your custom CRISPR model for lutein catabolic process research.
Frequently Asked Questions About lutein catabolic process
What is lutein catabolic process?
Lutein catabolic process (GO:0062172) is the set of chemical reactions and pathways that break down lutein, a non-provitamin A carotenoid [2,5].
What is the GO ID for lutein catabolic process?
The GO ID is GO:0062172, a biological_process term with synonyms lutein breakdown, lutein catabolism and lutein degradation.
What genes are involved in lutein catabolic process?
Candidate genes include carotenoid cleavage enzymes such as BCO2, transport proteins such as CD36 and SCARB1, and signaling genes such as NFKB1, PPARG and NLRP3 [2,3,4,7,8].
Why is lutein catabolic process important for eye health?
Lutein supplementation is studied for eye diseases, and its breakdown affects how long protective lutein concentrations persist in ocular tissues.
How does lutein catabolism relate to inflammation?
Lutein reduces inflammation by inhibiting ROS-mediated MAPK/NF-kB pathways, and its catabolism can influence the duration of these effects [3,4].
Is lutein a provitamin A carotenoid?
No, lutein is a non-provitamin A carotenoid, so it is not converted to vitamin A and must be cleared through catabolic routes.
What genetic factors affect lutein bioavailability?
Genetic factors involved in absorption and transport modulate lutein bioavailability, which in turn affects substrate availability for catabolism.
How can CRISPR be used to study lutein catabolic process?
CRISPR knockout, point mutation, knock-in and overexpression models can test the role of candidate enzymes and regulators in lutein breakdown.
What methods measure lutein catabolic rate?
HPLC-MS, RNA-seq, proteomics and cell-based signaling assays are commonly used to measure lutein and its degradation products [2,3,4].
Does lutein protect against cardiotoxicity?
Lutein, a non-provitamin A carotenoid, reduces cisplatin-induced cardiotoxicity in experimental models.
Conclusion
GO:0062172 lutein catabolic process describes the breakdown of lutein, a non-provitamin A carotenoid with protective roles in eye, intestinal, joint, heart and lung biology [1,3,4,5,7]. Its regulation involves substrate availability, genetic factors affecting bioavailability, membrane interactions and inflammatory signaling [3,4,6,7,8]. Understanding this process is important for optimizing lutein-based interventions and for biotechnological carotenoid production [1,2]. CRISPR-based cell models provide a powerful approach to dissect the enzymes and regulators of lutein catabolism.
References
- 1. Li LH et al.. 2020. Lutein Supplementation for Eye Diseases.. Nutrients 12(6) PMID: 32526861
- 2. Sandmann G. 2015. Carotenoids of biotechnological importance.. Adv Biochem Eng Biotechnol 148:449-67 PMID: 25326165
- 3. Yang LK et al.. 2025. Lutein reduces cisplatin-induced intestinal inflammation by inhibiting ROS-mediated MAPK/NF-κB pathways.. J Pharmacol Sci 159(4):292-300 PMID: 41241440
- 4. Chang CJ et al.. 2025. Lutein attenuates rheumatoid arthritis progression by suppressing MAPK/NF-κB signaling and MMP3 and MMP13 expression in fibroblast-like Synoviocytes.. Int Immunopharmacol 164:115360 PMID: 40815986
- 5. Gür FM et al.. 2025. Lutein, a non-provitamin A carotenoid, reduces cisplatin-induced cardiotoxicity.. Prostaglandins Other Lipid Mediat 177:106965 PMID: 39855459
- 6. McNulty H et al.. 2008. Biologic activity of carotenoids related to distinct membrane physicochemical interactions.. Am J Cardiol 101(10A):20D-29D PMID: 18474269
- 7. Nie C et al.. 2025. Lutein Alleviate Acute Lung Injury Induced by Limb Ischemia-Reperfusion Through PPAR-γ/PI3K/AKT/NLRP3 Signaling.. Mediators Inflamm 2025:2371545 PMID: 41292520
- 8. Bhat I et al.. 2021. Genetic factors involved in modulating lutein bioavailability.. Nutr Res 91:36-43 PMID: 34134039
